Goofice tablets 5 mg (hronic constipation)

General information about Japanese Goofice tablets 5 mg

Package details: 100 tablets

Manufacturer: EA Pharma, Japan.

Active ingredient: Elobixibat hydrate, 5 mg in each tablet

Medical effect: Goofice tablets 5 mg from Japan have following medical effects:

• suppressing reabsorption of bile acids,
• increases the flow of bile acids to the colon,
• promoting moisture and electrolyte secretion to the colon,
• enhancing bowel movement,
• therapeutic effect on chronic constipation.

Contraindications and precautions:

Do not use in children, pregnant or breastfeeding women. Cannot be used for patients with intestinal obstruction due to tumor or hernia. If an allergic reaction occurs, discontinue use. When used with other drugs, be sure to consult with your doctor as the elobixibat hydrate may interact with other ingredients.

Dosage and Administration of Japanese Goofice tablets against constipation:

Take 2 tablets once a day, before meal. The consulting doctor may adjust the dosage but the maximum of 3 tablets a day shall never be exceeded. 

About the effectiveness of Goofice tablets 5 mg from Japan

Goofice tablets 5 mg from Japan are effective against chronic constipation, caused by different reasons (excluding constipation due to organic diseases). This medicine is considered to be world’s first bile acid transporter inhibitor. EA Pharma has published the results of clinical studies, proving that Goofice tablets help with treatment of chronic constipation (EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce the results of phase 3 study of AJG533 for chronic constipation conducted in Japan – Primary endpoint met in patients with chronic constipation. Sep 2016. https://www.eapharma.co.jp/en/news/2016/0930.pdf ; Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment “GOOFICE® 5mg Tablet” Published in The Lancet Gastroenterology & Hepatology. Jul 2018. https://www.eapharma.co.jp/en/news/2018/0709.pdf ). Despite this is relatively new medicine, researchers all over the world have already reported great potential of the biloxibat (Andres Acosta and Michael Camiller. “Elobixibat and its potential role in chronic idiopathic constipation”. Therapeutic Advances in Gastroenterology, 2014 Jul; 7(4): 167–175; Yuji Kumagai, Hideki Amano et al. “Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial”. British Journal of Clinical Pharmacology, 2018 Oct; 84(10): 2393–2404.).